MSME (Udyam registered) Ministry of MSME
- Category
- Micro (2024-25)
- Udyam number
- UDYAM-KR-03-0054903
Rmeex Pharmaceutical Private Limited
Rmeex Pharmaceutical Private Limited - pharma in Bangalore, Karnataka, India. FY 2026 financials & compliance.
Revenue · FY 2024
₹75.16 Lakh
▲ 17% YoY
Net profit · FY 2024
₹1.99 Lakh
Net margin 2.7%
EBITDA · FY 2024
₹3.08 Lakh
EBITDA margin 4.1%
Authorised capital
₹1 Lakh
Registered with MCA
Paid-up capital
₹1 Lakh
Issued & subscribed
Open charges
₹35 Lakh
Secured borrowings
Company age
13 yrs
Est. 2013
Directors on board
2
As per MCA filings
About Rmeex Pharmaceutical Private Limited
Data last updated:
Rmeex Pharmaceutical Private Limited is a private limited company based in Bangalore, Karnataka, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 29 July 2013 and has been in existence for over 13 years.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U74900KA2013PTC070356. The company has 1 GST registration on record, which is no longer active.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Pratap Chandra Nayak and Rajesh Kumar Dash.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Sy No. 43 4th Floor Sgr Plaza Varthur Main Road Marathahalli, Bangalore, Karnataka, India – 560037.
As per the financials filed for FY 2024, the company reported a revenue of ₹75.16 Lakh, a growth of 17% compared to the previous year. For the same year it recorded a net profit of ₹1.99 Lakh (net margin 2.7%) and EBITDA of ₹3.08 Lakh (EBITDA margin 4.1%). Revenue has grown at a compounded annual rate (CAGR) of 7% over three years and 32% over five years.
As per MCA filings, the company has open charges of ₹35 Lakh on record.
Rmeex Pharmaceutical Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-KR-03-0054903). The current compliance status is marked as compliant by the Registrar of Companies.
Company details
CIN U74900KA2013PTC070356
Registration Number 070356
Incorporation Date 29 July 2013
ROC Bangalore
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Micro
Udyam Registration UDYAM-KR-03-0054903
Recognitions & Rankings of Rmeex Pharmaceutical
Contact details
Rmeex Pharmaceutical Private Limited's registered office is in Bangalore, Karnataka. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressSy No. 43 4th Floor Sgr Plaza Varthur Main Road Marathahalli, Bangalore, Karnataka, India – 560037
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Rmeex Pharmaceutical Private Limited, buy the company report.
Comprehensive company report
Rmeex Pharmaceutical Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Rmeex Pharmaceutical is trade. In detail, this covers retail trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G2 | Retail Trading |
To see the full business activity and turnover split of Rmeex Pharmaceutical Private Limited, buy the company report.
Financials of Rmeex Pharmaceutical Private Limited
FY 2025 filings availableRmeex Pharmaceutical Private Limited reported revenue of ₹75.16 Lakh (up 17% YoY) for FY 2024.
Revenue · FY 2024
₹75.16 Lakh ▲ 17%
Net profit · FY 2024
₹1.99 Lakh margin 2.7%
EBITDA · FY 2024
₹3.08 Lakh margin 4.1%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 17%
3 years · compounded
▲ 7%
5 years · compounded
▲ 32%
EBITDA CAGR growth
1 year
▲ 117%
3 years · compounded
▲ 140%
5 years · compounded
▲ 30%
Revenue has grown at a compounded annual rate (CAGR) of 32% over five years, including 17% growth in the latest year. EBITDA rose 117% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹3.08 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1.99 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 4.1% | ||||
| Net Profit Margin | 2.7% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Rmeex Pharmaceutical Private Limited, buy the company report.
Board of directors of Rmeex Pharmaceutical Private Limited
Rmeex Pharmaceutical has 2 directors on record. No former directors are listed.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Pratap Chandra Nayak Also directs: Neotric Pharmaceutical LLP, Uprise Staff Solutions Private Limited | Director | 29 Jul 2013 | 13 Years 2 Months | Current |
| Rajesh Kumar Dash Also directs: G2evolution Private Limited | Director | 29 Jul 2013 | 13 Years 2 Months | Current |
Peer comparison
Rmeex Pharmaceutical Private Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (retail trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Novell Pharma Private Limited | ₹75.42 Lakh (FY 2024) | 95.0% | Hyderabad, Telangana, India | |||
| Rmeex Pharmaceutical Private Limitedthis company | ₹75.16 Lakh (FY 2024) | ₹1.99 Lakh | 2.7% | 17.0% | Bangalore, Karnataka, India | |
| Edolf Healthcare Private Limited | ₹75.13 Lakh (FY 2024) | -42.0% | Chandigarh, India | |||
| Brio Vet Pharma Private Limited | ₹74.83 Lakh (FY 2025) | 15.0% | Kaithal, Haryana, India |
To see the full peer comparison of Rmeex Pharmaceutical Private Limited, buy the company report.
Auditor
Rmeex Pharmaceutical Private Limited is audited by PADARTHI & ASSOCIATES for the financial year 2020.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| PADARTHI & ASSOCIATES | FY 2020 | 010574S |
Shareholding
The shareholding of Rmeex Pharmaceutical Private Limited is on record for 3 financial years, the latest being FY 2020, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2020 | FY 2017 | FY 2016 |
|---|---|---|---|
| Promoters | |||
| Domestic institutional investors (DII) | |||
| Foreign institutional investors (FII) | |||
| Public | |||
| Others |
To see the full shareholding pattern of Rmeex Pharmaceutical Private Limited, buy the company report.
Charges & borrowings
Open charges
₹35 Lakh
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 29 Feb 2024 | 100898975 | Others | ₹35 Lakh | Open |
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Rmeex Pharmaceutical Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Rmeex Pharmaceutical Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Rmeex Pharmaceutical has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.
Total GSTINs
1
Cancelled / inactive
1
To see the full GST registrations and return filing status of Rmeex Pharmaceutical Private Limited, buy the company report.
Recent activity
Rmeex Pharmaceutical Private Limited has 2 board changes on record since 2013: 2 appointments. The latest: Pratap Chandra Nayak was appointed as Director on 29 Jul 2013.
AGM
Rmeex Pharmaceutical Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Rmeex Pharmaceutical Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Bangalore.
Charges
A charge with Others amounted to Rs. 35.00 Lakh with Charge ID 100898975 was registered on 29 Feb 2024.
Appointed
Pratap Chandra Nayak was appointed as Director.
Appointed
Rajesh Kumar Dash was appointed as Director.
Incorporation
29 Jul 2013
Rmeex Pharmaceutical Private Limited was registered on 29 Jul 2013 with Roc Bangalore & aged 13 years 2 months as per MCA records.
Frequently asked questions
Rmeex Pharmaceutical is an active private limited company based in Bangalore, Karnataka, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 29 July 2013 (13+ years old) and is registered under CIN U74900KA2013PTC070356.
Rmeex Pharmaceutical has 2 current directors:
- Pratap Chandra Nayak - Director
- Rajesh Kumar Dash - Director
The latest financial statements of Rmeex Pharmaceutical on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
No. Rmeex Pharmaceutical has 1 GST registration on record and it is cancelled or inactive.
The CIN (Corporate Identification Number) of Rmeex Pharmaceutical is U74900KA2013PTC070356. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Rmeex Pharmaceutical was incorporated on 29 July 2013, making it 13+ years old. It is registered with the Registrar of Companies, Bangalore.
The peers of Rmeex Pharmaceutical by revenue are Novell Pharma Private Limited, Edolf Healthcare Private Limited, Brio Vet Pharma Private Limited, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (retail trading).
Pratap Chandra Nayak was appointed as Director on 29 Jul 2013. Rajesh Kumar Dash was appointed as Director on 29 Jul 2013.
Yes, Rmeex Pharmaceutical is registered as a micro enterprise under Udyam registration (number: UDYAM-KR-03-0054903).
The registered office of Rmeex Pharmaceutical is at Sy No. 43 4th Floor Sgr Plaza Varthur Main Road Marathahalli, Bangalore, Karnataka, India – 560037.
Rmeex Pharmaceutical operates in the pharma industry, in the pharmaceutical retailers and distributors segment.